CervoMed to Present Results from Phase 2b Study
CervoMed Inc. (NASDAQ: CRVO) is gearing up to share significant findings from its Phase 2b RewinD-LB study at the upcoming Alzheimer’s Association International Conference (AAIC) in 2025. The company focuses on advancing treatments for age-related neurological disorders, particularly dementia with Lewy bodies (DLB). Attendees can look forward to detailed insights on the primary endpoint results after a 32-week Extension phase of the clinical trial.
Details of the Conference Call
The conference call is set for July 28 at 8:00 AM ET. This will be an opportunity for stakeholders to gain further understanding of the results, including the efficacy and safety of neflamapimod, the investigational drug being evaluated in the study. CervoMed encourages everyone to join the call to explore the implications of these findings, particularly about how they could influence the treatment landscape for DLB.
How to Join the Call
To join the conference call, participants can dial 1-877-425-9470 for domestic calls and 1-201-389-0878 for international participants. When prompted, use the passcode 13755139 to gain access. For added convenience, the company also offers a Call me™ feature, allowing participants to skip the waiting period associated with operator assistance.
Understanding the RewinD-LB Clinical Study
The RewinD-LB study is a landmark clinical trial exploring the potential benefits of neflamapimod, a small molecule designed to penetrate the brain effectively. This innovative approach targets p38 mitogen-activated protein kinase alpha, an important component in neurodegenerative processes affecting synaptic function. The trial involves a rigorous design: a 16-week randomized, double-blind, placebo-controlled phase followed by a 32-week treatment Extension phase.
Eligibility and Patient Profile
The study involves 159 patients diagnosed with DLB but specifically excludes individuals with Alzheimer’s disease co-pathology. This exclusion is critical as it ensures clarity in the results, especially since DLB patients with co-pathologies tend to exhibit different responses to treatments. The focus on “pure” DLB cases is aimed at garnering precise insights into the efficacy of neflamapimod.
Future Steps for CervoMed
CervoMed has positioned itself at the forefront of developing innovative treatments for neurodegenerative disorders. With neflamapimod currently evaluated in a Phase 2b study for DLB, there lies a significant potential to alter treatment paradigms for this challenging condition. The involvement of 43 sites across multiple countries underscores the importance of global collaboration in clinical research.
Funding and Support
The RewinD-LB study is primarily supported by a $21.3 million grant from the National Institutes of Health’s National Institute on Aging, reflecting robust backing for research into age-related diseases. This partnership underlines CervoMed's commitment to advancing scientific knowledge and patient care in neurology.
About CervoMed and its Mission
CervoMed is dedicated to tackling the complexities of age-related neurodegenerative disorders through innovative research and development. The company’s focus on oral medications like neflamapimod represents a proactive approach towards enhancing synaptic function and overall neurological health. As CervoMed continues to make strides in clinical research, their passion for improving the lives of those with DLB and similar conditions remains clear.
Frequently Asked Questions
What is the RewinD-LB study about?
The RewinD-LB study evaluates the efficacy of neflamapimod in patients with dementia with Lewy bodies through a randomized clinical trial.
When will the conference call take place?
The conference call is scheduled for July 28 at 8:00 AM ET.
How can I join the conference call?
You can join the conference call by dialing 1-877-425-9470 for domestic calls or 1-201-389-0878 for international calls, using the passcode 13755139.
What is neflamapimod?
Neflamapimod is an investigational oral medication designed to target neurological dysfunction through inhibition of a specific protein involved in cellular processes.
Who supports the RewinD-LB study financially?
The study is primarily funded by a significant grant from the National Institutes of Health’s National Institute on Aging, which highlights the importance of research in this field.
